Live
FierceBiotechMirum maps FDA path after anti-itch candidate scores ph. 2 winNovartisAfter March cuts, Novartis trims another 60 roles at US headquarters - Fierce PharmaFierceBiotechTakeda pivotal trial win improves convenience for PID patients relative to HyQviaBioWorldBiggest gainers and losers for April 27-May 1, 2026Endpoints NewsCelcuity breast cancer win; Odyssey plans $205M IPO; Latus Bio extends Series AFierceBiotechWindward catches $165M breeze to fuel long-acting TSLP ambitionsEndpoints NewsBiotech has a new startup model: Small team, big check and Chinese assetsThermo FisherThermo Fisher Scientific Introduces Gibco CTS DynaXS Single Use Bioreactor - Contract PharmaPfizerPfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era - Yahoo FinanceSiemens HealthineersCDC HoST-TT Certification for Siemens Healthineers Total Testosterone Test Expands Patient Access to Gold Standard Equivalent Results - The Manila TimesSiemens HealthineersSiemens Healthineers testosterone assay maintains CDC certification By Investing.com - Investing.com CanadaPharmaVoiceProtein degraders gain speed as Arvinas scores landmark approval
FierceBiotech Jan 22, 2026

Hoth strikes back against cancer drug skin toxicities, but share price stays frozen

Hoth strikes back against cancer drug skin toxicities, but share price stays frozen

Original
Body unavailable. Use the original source.